相关实验视频

Updated: Jan 9, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

伊卡里改善了与西斯普拉丁诱导的线粒体代谢功能障碍相关的毒性,并协同增强了其抗瘤功效

Piao Luo^1,2, Junhui Chen³, Yehai An¹

¹Guangdong Basic Research center of Excellence for Integrated Traditional and Western Medicine for Qingzhi Diseases, Guangdong provincial Key Laboratory of Chinese Medicine pharmaceutics, School of Traditional Chinese Medicine and School of pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|November 30, 2025

概括

西斯普拉丁化疗会通过损害线粒体和触发炎症而导致损伤. 伊卡里保护脏,并通过减少ROS和炎症来提高化疗的有效性.

科学领域:

生物化学生物化学
分子生物学分子生物学
毒理学毒理学毒理学

背景情况:

西斯 (CDDP) 是一种重要的化疗药物,但由于严重的毒性 (毒性),其使用受到限制.
驱动CDDP诱导的损伤的精确分子机制尚未完全理解.
了解这些机制对于改善癌症治疗和患者的治疗结果至关重要.

研究的目的:

使用集成的多组学阐明CDDP诱导的毒性分子机制.
确定治疗策略,以减轻CDDP诱导的脏损伤,并提高抗癌疗效.

主要方法:

综合多omics方法 (包括scRNA-seq) 用于分析脏组织.
调查了CDDP的直接约束性目标和下游信号通路.
在临床前模型中评估了岩素 (ICA) 的保护作用.

主要成果:

CDDP直接与线粒体蛋白质结合,破坏细胞代谢和呼吸.
CDDP诱导线粒体的活性氧物种 (ROS) 生产,激活NF-κB炎症途径.
靠近管状细胞是主要的目标;受损的细胞招募和激活免疫细胞,恶化损伤.
伊卡里 (ICA) 有效地减少ROS,抑制炎症,恢复新陈代谢平衡,并改善CDDP毒性.

结论:

CDDP毒性涉及线粒体功能障碍,ROS生成和炎症,特别是在近端管状细胞中.
伊卡里作为防治CDDP诱导的损伤的保护剂具有前景.
与ICA的联合治疗可以增强西斯的抗癌作用,同时减少脏副作用,提供双重效益的策略.

关键词:

西斯普拉丁 (cisplatin) 是一种制剂.现在我们可以看到icaritinitin.线粒体功能障碍线粒体功能障碍这是一个多主题的多omics.毒性毒性毒性

更多相关视频

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...